DGX Quest Diagnostics Incorporated Common Stock
NYSE · Health Care · SEC EDGAR で表示 ↗ 終値 10月 2, 2026 10-K/10-Q 7月 23, 2026
$233.33
· 52週範囲の%
· 安値より上
· 高値へ
$171.1852週安値
$248.8452週高値
時価総額 (MRQ)
$25.67B
P/E (TTM)
24.8
EPS (TTM)
$9.42
収益 (TTM)
$11.56B
あなたのバッジ
52週レンジ
$171–$249
アナリスト評価
HOLD
目標株価
$248
P/E
24.8
ROE
14.4%
純利益率
9.2%
バッジストリップは空です。このページ上の任意の指標をピン留めしてください。
DGX 株価スナップショット 価格、時価総額、P/E、EPS、ROE、負債/資本、52週レンジ
株価
$233.33
時価総額 (MRQ)
$25.67B
P/E (TTM)
24.8
EPS (TTM)
$9.42
収益 (TTM)
$11.56B
配当利回り
1.4%
ROE (TTM)
14.4%
負債/自己資本 (MRQ)
0.8
52週レンジ
$171–$249
DGX 株価チャート 技術指標付きの日次 OHLCV — パン、ズーム、ビューのカスタマイズ
範囲
バー
バーの粒度は選択した期間に合わせて調整されます。バーの始値/高値/安値/終値を確認するにはチャートにカーソルを合わせてください。
株式分割
| 権利落ち日 | 分割 | タイプ |
|---|---|---|
| 2005年6月21日 | 2-for-1 | 順 |
| 2001年6月1日 | 2-for-1 | 順 |
Quest Diagnostics Incorporated Common Stock について Wikipediaからの企業概要
Quest Diagnostics Incorporated is an American clinical laboratory. A Fortune 500 company, Quest operates in the United States, Puerto Rico, Mexico, and Brazil. Quest also maintains collaborative agreements with various hospitals and clinics across the globe.
As of 2020, the company had approximately 48,000 employees, and it generated more than $7.7 billion in revenue in 2019. The company offers access to diagnostic testing services for cancer, cardiovascular disease, infectious disease, neurological disorders, COVID-19, and employment and court-ordered drug testing.
History
1960–1995
Originally founded as Metropolitan Pathology Laboratory, Inc. in 1967 by Paul A. Brown, MD, the clinical laboratory underwent a variety of name changes. In 1969, the company's name changed to MetPath, Inc. with headquarters in Teaneck, New Jersey. By 1982, MetPath was acquired by what was then known as Corning Glass Works and was subsequently renamed Corning Clinical Laboratories.
1996–2000
On December 31, 1996, Quest Diagnostics became an independent company as a spin-off from Corning. Kenneth W. Freeman was appointed as CEO during this transition. Over the next year, Quest acquired a clinical laboratory division of Branford, Connecticut–based Diagnostic Medical Laboratory, Inc. (DML). Two years later in 1999, Quest added SmithKline Beecham Clinical Laboratories to their subsidiaries; which includes a joint venture ownership with CompuNet Clinical Laboratory. The purchase of SmithKline Beecham also included the lab's medical sample transport airline (ICAO: LBQ, call sign: LABQUEST) originally founded in 1988.
In 1997, Quest and Banner Health formed a joint venture creating the Arizona based Sonora Quest laboratory, a business unit of Laboratory Sciences of Arizona. This entity represents the operations of Quest Diagnostics in the Arizona regional market.
2001–2015
From May 2004 to April 2012, Surya Mohapatra served as the company's President and CEO. In 2007 Quest acquired diagnostic testing equipment company AmeriPath. In response to Mohapatra's resignation after eight years with Quest, former Philips Healthcare CEO Stephen Rusckowski was appointed. Under Rusckowski, Quest Diagnostics teamed up with central New England's largest health care system, UMass Memorial Health Care, to purchase its clinical outreach laboratory.
2016–present
In 2016, Quest collaborated with Safeway to bring testing services to twelve of its stores in California, Maryland, Virginia, Texas and Colorado.
By the end of 2017, Quest, in partnership with Walmart, incorporated laboratory testing in about 15 of their locations in Texas and Florida.
In May 2018, the company announced it will become an in-network laboratory provider to UnitedHealthcare starting in 2019, providing access to 48 million plan members.
In September 2018, Quest moved its headquarters from Madison, where it was located since 2007, to Secaucus, New Jersey.
In November 2018, Quest launched QuestDirect, a consumer-initiated testing service that allows patients to order health and wellness lab testing from home.
In March 2020, the company launched a COVID-19 testing service. As of July 2020, Quest had performed more than 9.2 million COVID-19 molecular tests and 2.8 million serology tests.
In April 2024, Quest has added a new blood screening to their AD-Detect product line. This test will analyze the blood for a specific Alzheimer's protein, pTau-217.
In February 2025, Quest acquired select assets of Fresenius Medical Care's Spectra laboratories. Under a separate agreement, Quest now offers clinical testing and lab services related to dialysis and end-stage kidney disease.
Acquisitions
Partnerships
2005: Forms a strategic alliance with Ciphergen Biosystems to commercialize novel proteomic tests.
Controversies
Quest Diagnostics set a record in April 2009 when it paid $302 million to the government to settle a Medicare fraud case alleging the company sold faulty medical testing kits. It was the largest qui tam (whistleblower) settlement paid by a medical laboratory for manufacturing and distributing a faulty product. In May 2011, Quest paid $241 million to the state of California to settle a False Claims Act case that alleged the company had overcharged Medi-Cal, the state's Medicaid program, and provided illegal kickbacks as incentives for healthcare providers to use Quest labs.
In 2018, Quest Diagnostics was among a number of U.S.–based laboratories linked to inaccuracies of over 200 women's cervical smear tests for CervicalCheck, Ireland's national screening program. Audits of the testing performed by Quest (and another subcontractor, Clinical Pathology Laboratories, Inc. of Austin, Texas) showed a high rate of errors in analysis of samples which led to lawsuits and a government inquiry. Quest and the Irish government continue to settle the resulting lawsuits.
On June 3, 2019, Quest announced that American Medical Collection Agency (AMCA), a billing collections service provider, had informed Quest Diagnostics that an unauthorized user had access to AMCA’s system containing personal information AMCA received from various entities, including from Quest. AMCA provides billing collections services to Optum360, which in turn is a Quest contractor. AMCA later went bankrupt after the breach.
出典: Wikipedia (英語), CC BY-SA 4.0 · Wikipediaで表示 ↗
セクターHealth Care
業種Health Care
従業員46,000
国US
10年間のパフォーマンス 収益、純利益、利益率、EPSのトレンド
収益$11.04B2016-12-31 → 2025-12-31
EPS$8.752016-12-31 → 2025-12-31
フリーキャッシュフロー$1.36B2016-12-31 → 2025-12-31
純利益率9.2%2016-12-31 → 2025-12-31
バリュエーションと指標
バリュエーション P/E、P/S、P/B、EV/EBITDA比率 — 株は割高か割安か？
| 指標 | 5年トレンド | DGX | 5年平均 | 競合中央値 | 結論 |
|---|---|---|---|---|---|
| P/E (TTM) | 24.85年平均 ≈17.7 | ≈17.7 | 23.3 | 割安 | |
| P/S (TTM) | 2.25年平均 ≈1.7 | ≈1.7 | 1.3 | 割高 | |
| 株価純資産倍率 (MRQ) | 3.45年平均 ≈2.7 | ≈2.7 | 2.9 | 適正価格 | |
| EV / EBITDA (EV/EBITDA) | 14.75年平均 ≈11.0 | ≈11.0 | 11.4 | 適正価格 | |
| 株価FCF倍率 (TTM) | 19.05年平均 ≈14.9 | ≈14.9 | · | · | |
| 株価収益率（P/CF） (TTM) | 13.55年平均 ≈10.8 | ≈10.8 | 9.8 | 適正価格 | |
| EV / Revenue (EV/売上高) | 2.85年平均 ≈2.2 | ≈2.2 | · | · | |
| EV / FCF (EV/FCF) | 22.95年平均 ≈18.8 | ≈18.8 | · | · | |
| 株価純資産倍率（P/TB） (MRQ) | 4.4 | · | · | · |
同業他社の中央値は、指標ごとに標準化された基準で計算されており、この銘柄に表示されているTTM/MRQ基準と常に一致するとは限りません。
収益性 粗利益率、営業利益率、純利益率、ROE、ROA、ROIC
| 指標 | 5年トレンド | DGX | 5年平均 | 競合中央値 | 結論 |
|---|---|---|---|---|---|
| 営業利益率 (TTM) | 14.1%5年平均 ≈15.6% | ≈15.6% | 8.3% | トップクラス | |
| EBITDAマージン (TTM) | 19.1%5年平均 ≈20.2% | ≈20.2% | 8.8% | トップクラス | |
| 税引前利益率 (TTM) | 12.1%5年平均 ≈14.5% | ≈14.5% | 3.8% | トップクラス | |
| 純利益率 (TTM) | 9.2%5年平均 ≈11.0% | ≈11.0% | 5.1% | トップクラス | |
| ROA (TTM) | 6.5%5年平均 ≈8.0% | ≈8.0% | 4.0% | トップクラス | |
| ROE (TTM) | 14.4%5年平均 ≈17.4% | ≈17.4% | 12.5% | 同水準 | |
| ROIC | 9.2%5年平均 ≈11.0% | ≈11.0% | 9.2% | 同水準 |
財務健全性 負債、流動性、支払能力 — バランスシートの健全性
| 指標 | 5年トレンド | DGX | 5年平均 | 競合中央値 | 結論 |
|---|---|---|---|---|---|
| 負債資本倍率 (MRQ) | 0.85年平均 ≈0.8 | ≈0.8 | 0.4 | 高負債 | |
| 流動比率 (MRQ) | 1.65年平均 ≈1.2 | ≈1.2 | 1.4 | 高流動性 | |
| Quick Ratio (クイックレシオ) | 0.85年平均 ≈1.0 | ≈1.0 | 0.8 | 高流動性 | |
| 長期負債/株主資本 (MRQ) | 0.75年平均 ≈0.7 | ≈0.7 | 0.7 | 高負債 |
成長 収益、EPS、純利益の成長率：前年比、3年CAGR、5年CAGR
| 指標 | 5年トレンド | DGX | 5年平均 | 競合中央値 | 結論 |
|---|---|---|---|---|---|
| Revenue YoY (収益（前年比）) | 11.8%5年平均 ≈3.6% | ≈3.6% | · | · | |
| Revenue CAGR 3Y (収益（3年CAGR）) | 3.7%5年平均 ≈0.06% | ≈0.06% | · | · | |
| Revenue CAGR 5Y (収益（5年CAGR）) | 3.2% | · | · | · | |
| EPS YoY | 13.8%5年平均 ≈2.0% | ≈2.0% | · | · | |
| Net Income YoY (純利益（前年比）) | 13.9%5年平均 ≈-1.4% | ≈-1.4% | · | · | |
| EPS CAGR 3Y (EPS年平均成長率 3年) | 3.2%5年平均 ≈-9.4% | ≈-9.4% | · | · | |
| EPS CAGR 5Y (EPS年平均成長率 5年) | -3.5% | · | · | · | |
| Net Income CAGR 3Y (純利益年平均成長率 3年) | 1.6%5年平均 ≈-12.8% | ≈-12.8% | · | · | |
| Net Income CAGR 5Y (純利益年平均成長率 5年) | -7.1% | · | · | · |
資本効率 総資産回転率、棚卸資産回転率、売掛金回転率
| 指標 | 5年トレンド | DGX | 5年平均 | 競合中央値 | 結論 |
|---|---|---|---|---|---|
| Asset Turnover (総資産回転率) | 0.75年平均 ≈0.7 | ≈0.7 | 1.2 | 弱い | |
| Inventory Turnover (棚卸資産回転率) | 39.15年平均 ≈33.9 | ≈33.9 | 15.6 | トップクラス | |
| Receivables Turnover (売掛金回転率) | 8.15年平均 ≈7.7 | ≈7.7 | 10.5 | 弱い | |
| Revenue / Employee (年間売上高 ÷ 従業員数（yfinanceの報告ヘッドカウント）。派生値 — SEC-XBRLの保存概念ではありません。) | ≈$239.9K | · | · | · |
バリュエーション · ≈ 5年平均 · 業界中央値 · 中央値に対する評価
配当金 利回り、配当性向、配当履歴、5年CAGR
配当利回り1.4%
配当性向35.6%
年次配当≈$3.44
5年配当CAGR≈7.4%
成長連続記録≈14
| 権利落ち日 | 金額 | 通貨 | 利回り |
|---|---|---|---|
| 7月 8, 2026 | $0.86 | USD | ≈1.6% |
| 4月 6, 2026 | $0.86 | USD | ≈1.6% |
| 1月 13, 2026 | $0.80 | USD | ≈1.8% |
| 10月 3, 2025 | $0.80 | USD | ≈1.8% |
| 7月 7, 2025 | $0.80 | USD | ≈1.8% |
| 4月 7, 2025 | $0.80 | USD | ≈1.9% |
| 1月 14, 2025 | $0.75 | USD | ≈2.0% |
| 10月 4, 2024 | $0.75 | USD | ≈2.0% |
| 7月 8, 2024 | $0.75 | USD | ≈2.1% |
| 4月 5, 2024 | $0.75 | USD | ≈2.2% |
| 1月 16, 2024 | $0.71 | USD | ≈2.1% |
| 10月 5, 2023 | $0.71 | USD | ≈2.3% |
| 7月 10, 2023 | $0.71 | USD | ≈2.0% |
| 4月 6, 2023 | $0.71 | USD | ≈1.9% |
| 1月 17, 2023 | $0.66 | USD | ≈1.8% |
| 10月 3, 2022 | $0.66 | USD | ≈2.1% |
| 7月 5, 2022 | $0.66 | USD | ≈1.9% |
| 4月 5, 2022 | $0.66 | USD | ≈1.9% |
| 1月 18, 2022 | $0.62 | USD | ≈1.8% |
| 10月 4, 2021 | $0.62 | USD | ≈1.7% |
決算履歴 EPS実績 vs 予想、サプライズ%、達成率、次回決算日
平均サプライズ
3.6%
次回決算
10月 19, 2026
| 期間 | レポート | EPS Actual | EPS 予想 | サプライズ |
|---|---|---|---|---|
| 2026年6月30日 | 7月 20, 2026 | $3.12 | $2.85 | 9.3% |
| 2026年3月31日 | $2.50 | $2.37 | 5.5% | |
| 2025年12月31日 | $2.42 | $2.38 | 1.5% | |
| 2025年9月30日 | $2.60 | $2.53 | 2.8% | |
| 2025年6月30日 | $2.62 | $2.60 | 0.93% | |
| 2025年3月31日 | $2.21 | $2.17 | 1.7% |
完全なファンダメンタルズ 年次別全指標 — 損益計算書、貸借対照表、キャッシュフロー
損益計算書
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $11.04B | $9.87B | $9.25B | $9.88B | $10.79B | $9.44B | $7.73B | $7.53B | $7.40B | $7.21B | $7.49B | $7.43B | |
| Cost of Revenue | $7.37B | $6.63B | $6.20B | $6.45B | $6.58B | $5.80B | $5.04B | $4.93B | $4.72B | $4.62B | $4.66B | $4.64B | |
| Gross Profit | · | · | · | · | · | $3.63B | $2.69B | $2.60B | $2.68B | $2.90B | $2.84B | $2.80B | |
| SG&A Expense | $1.97B | $1.77B | $1.64B | $1.87B | $1.73B | $1.55B | $1.46B | $1.42B | $1.44B | $1.38B | $1.68B | $1.73B | |
| Operating Expenses | $9.48B | $8.53B | $7.99B | $8.46B | $8.41B | $7.47B | $6.50B | $6.43B | $6.24B | $5.94B | $6.09B | $6.45B | |
| Operating Income | $1.56B | $1.35B | $1.26B | $1.43B | $2.38B | $1.97B | $1.23B | $1.10B | $1.17B | $1.28B | $1.40B | $983M | |
| Interest Expense | · | · | $163M | $148M | $152M | $166M | $180M | $169M | $153M | $144M | $154M | $167M | |
| Interest Income | $13M | $25M | $11M | $10M | $1M | $3M | $5M | $2M | $2M | $1M | $1M | $3M | |
| Other Non-op | $26M | $30M | $20M | $-55M | $369M | $76M | $20M | $-8M | $16M | $-48M | $-143M | $4M | |
| Pretax Income | $1.32B | $1.18B | $1.13B | $1.24B | $2.60B | $1.88B | $1.08B | $926M | $1.03B | $1.09B | $1.10B | $823M | |
| Income Tax | $314M | $273M | $248M | $264M | $597M | $460M | $247M | $182M | $241M | $429M | $373M | $262M | |
| Net Income | $992M | $871M | $854M | $946M | $2.00B | $1.43B | $858M | $736M | $772M | $645M | $709M | $556M | |
| EPS (Basic) | $8.87 | $7.78 | $7.59 | $8.10 | $15.85 | $10.62 | $6.36 | $5.39 | $5.63 | $4.58 | $4.92 | $3.83 | |
| EPS (Diluted) | $8.75 | $7.69 | $7.49 | $7.97 | $15.55 | $10.47 | $6.28 | $5.29 | $5.50 | $4.51 | $4.87 | $3.81 | |
| Shares (Basic) | 111,000,000 | 111,000,000 | 112,000,000 | 116,000,000 | 125,000,000 | 134,000,000 | 134,000,000 | 136,000,000 | 137,000,000 | 140,000,000 | 144,000,000 | 145,000,000 | |
| Shares (Diluted) | 113,000,000 | 113,000,000 | 113,000,000 | 118,000,000 | 128,000,000 | 136,000,000 | 136,000,000 | 139,000,000 | 140,000,000 | 142,000,000 | 145,000,000 | 145,000,000 | |
| EBITDA | $2.13B | $1.84B | $1.70B | $1.86B | $2.79B | $2.33B | $1.56B | $1.41B | $1.44B | $1.53B | $1.70B | $1.30B |
貸借対照表
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $420M | $549M | $686M | $315M | $872M | $1.16B | $1.19B | $135M | $137M | $359M | $133M | $192M | |
| Receivables | $1.41B | $1.30B | $1.21B | $1.20B | $1.44B | $1.52B | $1.06B | $1.01B | $924M | $926M | $901M | $932M | |
| Inventory | $189M | $188M | $190M | $192M | $208M | $223M | $123M | $99M | $95M | $82M | $84M | $110M | |
| Prepaid Expense | $361M | $351M | $286M | $196M | $223M | $157M | $112M | $144M | $150M | $155M | $207M | $186M | |
| Current Assets | $2.38B | $2.39B | $2.37B | $1.90B | $2.74B | $3.06B | $2.49B | $1.39B | $1.31B | $1.53B | $1.50B | $1.60B | |
| PP&E (Net) | $2.20B | $2.11B | $1.82B | $1.77B | $1.71B | $1.63B | $1.45B | $1.29B | $1.15B | $1.03B | $925M | $933M | |
| PP&E (Gross) | $6.18B | $5.77B | $5.23B | $5.10B | $4.79B | $4.62B | $4.23B | $3.97B | $3.67B | $3.43B | $3.23B | $3.13B | |
| Accum. Depreciation | $3.97B | $3.66B | $3.42B | $3.34B | $3.09B | $2.99B | $2.78B | $2.68B | $2.53B | $2.40B | $2.31B | $2.19B | |
| Goodwill | $8.95B | $8.86B | $7.73B | $7.22B | $7.09B | $6.87B | $6.62B | $6.56B | $6.33B | $6.00B | $5.91B | $6.03B | |
| Intangibles | $1.64B | $1.76B | $1.17B | $1.09B | $1.17B | $1.17B | $1.12B | $1.21B | $1.12B | $949M | $984M | $1.07B | |
| Other Non-current Assets | $270M | $255M | $198M | $144M | $163M | $176M | $160M | $119M | $136M | $148M | $174M | $172M | |
| Total Assets | $16.23B | $16.15B | $14.02B | $12.84B | $13.61B | $14.03B | $12.84B | $11.00B | $10.50B | $10.10B | $9.96B | $9.86B | |
| Accounts Payable | $1.60B | $1.39B | $1.36B | $1.40B | $1.60B | $1.63B | $1.04B | $1.02B | $1.02B | $975M | $1.01B | $1.19B | |
| Accrued Liabilities | $338M | $306M | $287M | $392M | $460M | $356M | $223M | $274M | $246M | $254M | $257M | $277M | |
| Current Liabilities | $2.28B | $2.17B | $1.81B | $1.55B | $1.75B | $1.78B | $1.99B | $1.49B | $1.06B | $981M | $1.17B | $1.71B | |
| Capital Leases | $537M | $535M | $503M | $489M | $494M | $499M | $413M | $0 | · | · | · | · | |
| Deferred Tax | · | · | · | · | · | · | $264M | $243M | $170M | $191M | $157M | $204M | |
| Other Non-current Liabilities | $957M | $938M | $876M | $812M | $792M | $847M | $711M | $745M | $663M | $654M | $514M | $594M | |
| Long-term Debt | $5.67B | $6.22B | $4.71B | $3.98B | $4.01B | $4.01B | $4.77B | $3.89B | $3.78B | $3.73B | $3.65B | $3.74B | |
| Total Debt | $5.67B | $6.22B | $4.71B | $3.98B | $4.01B | $4.01B | $4.77B | $3.89B | $3.78B | $3.73B | $3.65B | $3.76B | |
| Common Stock | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | |
| Retained Earnings | $9.99B | $9.36B | $8.82B | $8.29B | $7.65B | $9.30B | $8.17B | $7.60B | $7.14B | $6.61B | $6.20B | $5.72B | |
| Treasury Stock | $5.18B | $4.86B | $4.83B | $4.67B | $3.45B | $5.37B | $5.22B | $5.00B | $4.78B | $4.46B | $3.96B | $3.81B | |
| AOCI | $-27M | $-88M | $-14M | $-21M | $-14M | $-21M | $-39M | $-59M | $-48M | $-72M | $-38M | $-27M | |
| Stockholders' Equity | $7.17B | $6.78B | $6.31B | $5.89B | $6.44B | $6.76B | $5.64B | $5.22B | $4.92B | $4.63B | $4.68B | $4.30B | |
| Liabilities + Equity | $16.23B | $16.15B | $14.02B | $12.84B | $13.61B | $14.03B | $12.84B | $11.00B | $10.50B | $10.10B | $9.96B | $9.86B | |
| Shares Outstanding | 110,000,000 | 111,000,000 | 111,000,000 | 111,000,000 | 119,000,000 | 133,000,000 | 133,000,000 | 135,000,000 | 135,000,000 | 137,000,000 | 143,000,000 | 144,000,000 |
キャッシュフロー
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $570M | $493M | $439M | $437M | $408M | $361M | $329M | $309M | $270M | $249M | $304M | $314M | |
| Stock-based Comp | $88M | $88M | $77M | $77M | $79M | $97M | $56M | $61M | $79M | $69M | $52M | $51M | |
| Deferred Tax | $105M | $13M | $-49M | $1M | $-57M | $85M | $15M | $73M | $9M | $37M | $112M | $23M | |
| Amort. of Intangibles | $154M | $127M | $108M | $120M | $103M | $103M | $96M | $90M | $74M | $72M | $81M | $94M | |
| Restructuring | · | · | · | $55M | $13M | $14M | $-3M | $49M | $30M | $11M | $39M | $43M | |
| Other Non-cash | $131M | $-131M | $-49M | $257M | $-192M | $31M | $-15M | $21M | $45M | $69M | $-367M | $-6M | |
| Operating Cash Flow | $1.89B | $1.33B | $1.27B | $1.72B | $2.23B | $2.00B | $1.24B | $1.20B | $1.18B | $1.12B | $821M | $944M | |
| CapEx | $527M | $425M | $408M | $404M | $403M | $418M | $400M | $383M | $252M | $293M | $263M | $308M | |
| Investing Cash Flow | $-631M | $-2.55B | $-1.06B | $-543M | $21M | $-772M | $-411M | $-801M | $-830M | $-127M | $-362M | $-1.02B | |
| Stock Repurchased | $450M | $151M | $275M | $1.41B | $2.20B | $325M | $353M | $322M | $465M | $590M | $224M | $132M | |
| Net Stock Activity | $-450M | $-151M | $-275M | $-1.41B | $-2.20B | $-325M | $-353M | $-322M | $-465M | $-590M | $-224M | $-132M | |
| Dividends Paid | $353M | $331M | $314M | $305M | $309M | $297M | $286M | $266M | $247M | $223M | $212M | $187M | |
| Financing Cash Flow | $-1.39B | $1.08B | $160M | $-1.73B | $-2.54B | $-1.27B | $225M | $-401M | $-592M | $-738M | $-518M | $86M | |
| Net Change in Cash | $-129M | $-137M | $371M | $-557M | $-286M | · | · | · | $-222M | $226M | $-59M | $5M | |
| Taxes Paid | $169M | $256M | $317M | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $1.36B | $909M | $864M | $1.31B | $1.83B | $1.59B | $843M | $817M | $923M | $776M | $547M | $630M | |
| Levered FCF | · | · | $737M | $1.20B | $1.71B | $1.46B | $704M | $681M | $806M | $689M | · | · |
収益性
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | · | · | · | · | · | 38.5% | 34.8% | 34.6% | 38.8% | 38.6% | 37.9% | 37.6% | |
| Operating Margin | 14.1% | 13.6% | 13.6% | 14.4% | 22.1% | 20.9% | 15.9% | 14.6% | 15.1% | 17.0% | 18.7% | 13.2% | |
| Net Margin | 9.0% | 8.8% | 9.2% | 9.6% | 18.5% | 15.2% | 11.1% | 9.8% | 10.0% | 8.6% | 9.5% | 7.5% | |
| Pretax Margin | 11.9% | 11.9% | 12.2% | 12.5% | 24.1% | 20.0% | 13.9% | 12.3% | 13.4% | 14.4% | 14.7% | · | |
| EBITDA Margin | 19.3% | 18.6% | 18.4% | 18.9% | 25.9% | 24.7% | 20.2% | 18.7% | 18.6% | 20.3% | 22.7% | 17.4% | |
| ROA | 6.1% | 5.8% | 6.4% | 7.1% | 14.4% | 10.7% | 7.2% | 6.8% | 7.5% | 6.4% | 7.1% | 5.9% | |
| ROE | 14.2% | 13.3% | 14.0% | 15.3% | 30.2% | 23.1% | 15.8% | 14.5% | 16.2% | 13.9% | 15.8% | 13.5% | |
| ROIC | 9.2% | 8.0% | 8.9% | 11.4% | 17.5% | 13.8% | 9.1% | 9.7% | 10.2% | 9.2% | 11.1% | · |
流動性と支払能力
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.0 | 1.1 | 1.3 | 1.2 | 1.6 | 1.7 | 1.3 | 0.9 | 1.2 | 1.6 | 1.3 | 0.9 | |
| Quick Ratio | 0.8 | 0.9 | 1.0 | 1.0 | 1.3 | 1.5 | 1.1 | 0.8 | 1.0 | 1.3 | 0.9 | 0.7 | |
| Debt / Equity | 0.8 | 0.9 | 0.7 | 0.7 | 0.6 | 0.6 | 0.8 | 0.7 | 0.8 | 0.8 | 0.8 | 0.9 | |
| LT Debt / Equity | 0.7 | 0.8 | 0.7 | 0.7 | 0.6 | 0.6 | 0.7 | 0.7 | 0.8 | 0.8 | 0.7 | 0.8 | |
| Interest Coverage | · | · | 7.7 | 9.6 | 15.7 | 11.9 | 6.8 | 6.5 | 7.6 | 8.9 | · | · |
効率性
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.7 | 0.7 | 0.7 | 0.7 | 0.8 | 0.7 | 0.6 | 0.7 | 0.7 | 0.7 | 0.8 | 0.8 | |
| Inventory Turnover | 39.1 | 35.1 | 32.5 | 32.2 | 30.5 | 33.5 | 45.4 | 50.8 | 53.3 | 55.6 | 48.0 | 46.1 | |
| Receivables Turnover | 8.1 | 7.9 | 7.7 | 7.5 | 7.3 | 7.3 | 7.4 | 7.8 | 8.3 | 8.2 | 8.2 | 8.3 |
1株あたり
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $65.18 | $61.06 | $56.82 | $53.09 | $54.15 | $50.82 | $42.41 | $38.64 | $36.45 | $33.78 | $32.76 | $29.87 | |
| Revenue / Share | $97.65 | $87.36 | $81.88 | $83.75 | $84.28 | $69.39 | $56.81 | $54.18 | $55.06 | $52.92 | $51.68 | $51.28 | |
| Cash Flow / Share | $16.69 | $11.81 | $11.26 | $14.56 | $17.45 | $14.74 | $9.14 | $8.63 | $8.39 | $7.53 | $5.59 | $6.47 | |
| Cash / Share | $3.82 | $4.95 | $6.18 | $2.84 | $7.33 | $8.71 | $8.96 | $1.00 | $1.01 | $2.62 | $0.93 | $1.33 | |
| Dividend / Share | · | · | · | · | · | · | · | · | $1.80 | $1.65 | $1.52 | $1.32 | |
| EPS (TTM) | $8.75 | $7.69 | $7.49 | $7.97 | $15.55 | $10.47 | $6.28 | $5.29 | $5.50 | $4.51 | $4.87 | $3.81 |
成長率
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 11.8% | 6.7% | -6.4% | -8.4% | 14.3% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 3.7% | -2.9% | -0.66% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 3.2% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | 13.8% | 2.7% | -6.0% | -48.8% | 48.5% | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | 3.2% | -20.9% | -10.6% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | -3.5% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | 13.9% | 2.0% | -9.7% | -52.6% | 39.4% | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | 1.6% | -24.1% | -15.8% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | -7.1% | · | · | · | · | · | · | · | · | · | · | · | |
| Dividends Paid CAGR 5Y | 3.5% | · | · | · | · | · | · | · | · | · | · | · |
バリュエーション（TTM）
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $11.04B | $9.87B | $9.25B | $9.88B | $10.79B | $9.44B | $7.73B | $7.53B | $7.40B | $7.21B | $7.49B | $7.43B | |
| Net Income TTM | $992M | $871M | $854M | $946M | $2.00B | $1.43B | $858M | $736M | $772M | $645M | $709M | $556M | |
| Market Cap | $19.09B | $16.75B | $15.30B | $17.36B | $20.59B | $15.85B | $14.20B | $11.24B | $13.30B | $12.59B | $10.17B | $9.66B | |
| Enterprise Value | $24.34B | $22.41B | $19.33B | $21.03B | $23.73B | $18.71B | $17.78B | $15.00B | $16.94B | $15.97B | $13.69B | $13.23B | |
| P/E | 19.8 | 19.6 | 18.4 | 19.6 | 11.1 | 11.4 | 17.0 | 15.7 | 17.9 | 20.4 | 14.6 | 17.6 | |
| P/S | 1.7 | 1.7 | 1.7 | 1.8 | 1.9 | 1.7 | 1.8 | 1.5 | 1.8 | 1.7 | 1.4 | 1.3 | |
| P/B | 2.7 | 2.5 | 2.4 | 2.9 | 3.2 | 2.3 | 2.5 | 2.2 | 2.7 | 2.7 | 2.2 | 2.2 | |
| P / Cash Flow | 10.1 | 12.6 | 12.0 | 10.1 | 9.2 | 7.9 | 11.4 | 9.4 | 11.3 | 11.8 | 12.6 | 10.3 | |
| P / FCF | 14.0 | 18.4 | 17.7 | 13.2 | 11.3 | 10.0 | 16.8 | 13.8 | 14.4 | 16.2 | 18.6 | 15.3 | |
| EV / EBITDA | 11.4 | 12.2 | 11.4 | 11.3 | 8.5 | 8.0 | 11.4 | 10.6 | 11.8 | 10.5 | 8.0 | 10.2 | |
| EV / FCF | 17.9 | 24.7 | 22.4 | 16.0 | 13.0 | 11.8 | 21.1 | 18.4 | 18.4 | 20.6 | 25.0 | 21.0 | |
| EV / Revenue | 2.2 | 2.3 | 2.1 | 2.1 | 2.2 | 2.0 | 2.3 | 2.0 | 2.3 | 2.2 | 1.8 | 1.8 | |
| Dividend Yield | 1.8% | 2.0% | 2.1% | 1.8% | 1.5% | 1.9% | 2.0% | 2.4% | 1.9% | 1.8% | 2.1% | 1.9% | |
| Earnings Yield | 5.0% | 5.1% | 5.4% | 5.1% | 9.0% | 8.8% | 5.9% | 6.3% | 5.6% | 4.9% | 6.9% | 5.7% | |
| Payout Ratio | 35.6% | 38.0% | 36.8% | 32.2% | 15.5% | 20.8% | 33.3% | 36.1% | 32.0% | 34.6% | 29.9% | 33.6% | |
| Annual Payout | $353M | $331M | $314M | $305M | $309M | $297M | $286M | $266M | $247M | $223M | $212M | $187M |
損益計算書
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.04B | $2.90B | $2.81B | $2.82B | $2.76B | $2.65B | $2.62B | $2.49B | $2.40B | $2.37B | $2.29B | $2.29B | $2.34B | $2.33B | $2.33B | $2.49B | |
| Cost of Revenue | $2.02B | $1.95B | $1.90B | $1.87B | $1.82B | $1.79B | $1.76B | $1.68B | $1.59B | $1.59B | $1.55B | $1.54B | $1.55B | $1.56B | $1.57B | $1.62B | |
| SG&A Expense | $529M | $504M | $504M | $501M | $486M | $476M | $466M | $448M | $416M | $440M | $407M | $380M | $416M | $439M | $563M | $464M | |
| Operating Expenses | $2.58B | $2.50B | $2.42B | $2.43B | $2.32B | $2.31B | $2.26B | $2.16B | $2.04B | $2.07B | $2.02B | $1.95B | $1.99B | $2.03B | $2.20B | $2.09B | |
| Operating Income | $459M | $399M | $386M | $386M | $438M | $346M | $361M | $330M | $355M | $300M | $267M | $342M | $348M | $305M | $135M | $392M | |
| Interest Expense | · | · | · | · | · | · | · | · | $47M | $49M | · | $41M | $39M | $37M | · | $37M | |
| Interest Income | $5M | $2M | $3M | $3M | $2M | $5M | $7M | $9M | $3M | $6M | $6M | $1M | $2M | $2M | $4M | $4M | |
| Other Non-op | $16M | $-2M | $8M | $8M | $13M | $-3M | $3M | $15M | $3M | $9M | $10M | $-3M | $6M | $7M | $6M | $-8M | |
| Pretax Income | $412M | $334M | $330M | $328M | $384M | $276M | $299M | $296M | $314M | $266M | $237M | $299M | $317M | $277M | $109M | $351M | |
| Income Tax | $88M | $74M | $81M | $77M | $97M | $59M | $68M | $65M | $74M | $66M | $40M | $68M | $75M | $65M | $-4M | $81M | |
| Net Income | $320M | $252M | $245M | $245M | $282M | $220M | $222M | $226M | $229M | $194M | $192M | $225M | $235M | $202M | $101M | $256M | |
| EPS (Basic) | $2.88 | $2.27 | $2.21 | $2.18 | $2.51 | $1.97 | $1.98 | $2.01 | $2.05 | $1.74 | $1.72 | $1.99 | $2.08 | $1.80 | $0.93 | $2.20 | |
| EPS (Diluted) | $2.84 | $2.24 | $2.18 | $2.16 | $2.47 | $1.94 | $1.95 | $1.99 | $2.03 | $1.72 | $1.70 | $1.96 | $2.05 | $1.78 | $0.92 | $2.17 | |
| Shares (Basic) | 111,000,000 | 110,000,000 | · | 112,000,000 | 112,000,000 | 111,000,000 | · | 112,000,000 | 111,000,000 | 111,000,000 | · | 112,000,000 | 112,000,000 | 112,000,000 | · | 116,000,000 | |
| Shares (Diluted) | 112,000,000 | 112,000,000 | · | 113,000,000 | 113,000,000 | 113,000,000 | · | 113,000,000 | 112,000,000 | 112,000,000 | · | 114,000,000 | 114,000,000 | 113,000,000 | · | 118,000,000 | |
| EBITDA | $605M | $546M | · | $528M | $581M | $486M | · | $455M | $472M | $416M | · | $453M | $460M | $412M | · | $500M |
貸借対照表
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $626M | $393M | $420M | $432M | $319M | $188M | $549M | $764M | $271M | $474M | · | $143M | $126M | $175M | · | $700M | |
| Receivables | $1.67B | $1.59B | $1.41B | $1.46B | $1.42B | $1.40B | $1.30B | $1.38B | $1.32B | $1.32B | · | $1.28B | $1.24B | $1.25B | · | $1.28B | |
| Inventory | $233M | $225M | $189M | $186M | $187M | $189M | $188M | $184M | $182M | $181M | · | $184M | $184M | $190M | · | $183M | |
| Prepaid Expense | $319M | $361M | $361M | $333M | $273M | $294M | $351M | $299M | $245M | $251M | · | $207M | $188M | $195M | · | $171M | |
| Current Assets | $2.84B | $2.57B | $2.38B | $2.41B | $2.20B | $2.08B | $2.39B | $2.62B | $2.02B | $2.23B | · | $1.81B | $1.73B | $1.81B | · | $2.33B | |
| PP&E (Net) | $2.22B | $2.19B | $2.20B | $2.15B | $2.12B | $2.10B | $2.11B | $2.09B | $1.83B | $1.81B | · | $1.83B | $1.81B | $1.79B | · | $1.71B | |
| PP&E (Gross) | · | · | $6.18B | · | · | · | $5.77B | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $3.97B | · | · | · | $3.66B | · | · | · | · | · | · | · | · | · | |
| Goodwill | $9.11B | $9.12B | $8.95B | $8.90B | $8.88B | $8.85B | $8.86B | $8.61B | $7.88B | $7.83B | $7.73B | $7.73B | $7.73B | $7.24B | $7.22B | $7.19B | |
| Intangibles | $1.67B | $1.72B | $1.64B | $1.66B | $1.71B | $1.73B | $1.76B | $1.72B | $1.20B | $1.19B | · | $1.22B | $1.25B | $1.08B | · | $1.11B | |
| Other Non-current Assets | $277M | $256M | $270M | $296M | $271M | $260M | $255M | $272M | $216M | $182M | · | $149M | $152M | $150M | · | $132M | |
| Total Assets | $16.94B | $16.67B | $16.23B | $16.20B | $15.97B | $15.80B | $16.15B | $16.09B | $13.88B | $13.95B | · | $13.48B | $13.43B | $12.79B | · | $13.22B | |
| Accounts Payable | $1.60B | $1.50B | $1.60B | $1.46B | $1.35B | $1.27B | $1.39B | $1.31B | $1.25B | $1.24B | · | $1.16B | $1.20B | $1.20B | · | $1.45B | |
| Accrued Liabilities | · | · | $338M | · | · | · | $306M | · | · | · | · | · | · | · | · | · | |
| Current Liabilities | $1.79B | $2.18B | $2.28B | $2.13B | $2.02B | $1.44B | $2.17B | $2.09B | $2.01B | $2.30B | · | $1.62B | $1.88B | $1.35B | · | $1.60B | |
| Capital Leases | $561M | $574M | $537M | $534M | $540M | $538M | $535M | $543M | $507M | $489M | · | $505M | $508M | $490M | · | $505M | |
| Other Non-current Liabilities | $1.06B | $1.02B | $957M | $982M | $890M | $917M | $938M | $891M | $811M | $817M | · | $874M | $901M | $809M | · | $787M | |
| Long-term Debt | $5.64B | · | $5.67B | · | · | · | $6.22B | $6.25B | · | · | · | · | · | · | · | · | |
| Total Debt | $5.64B | $503M | · | $504M | $504M | $1M | · | $6.25B | $606M | $906M | · | $304M | $518M | $2M | · | $2M | |
| Common Stock | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | · | $2M | $2M | $2M | · | $2M | |
| Retained Earnings | $10.37B | $10.15B | $9.99B | $9.84B | $9.68B | $9.49B | $9.36B | $9.22B | $9.08B | $8.94B | · | $8.71B | $8.57B | $8.41B | · | $8.26B | |
| Treasury Stock | $5.17B | $5.09B | $5.18B | $4.90B | $4.77B | $4.79B | $4.86B | $4.73B | $4.76B | $4.78B | · | $4.57B | $4.59B | $4.61B | · | $4.27B | |
| AOCI | $-62M | $-43M | $-27M | $-40M | $-16M | $-83M | $-88M | $-15M | $-19M | $-16M | · | $-20M | $-16M | $-18M | · | $-31M | |
| Stockholders' Equity | $7.52B | $7.37B | $7.17B | $7.26B | $7.23B | $6.93B | $6.78B | $6.81B | $6.62B | $6.43B | · | $6.42B | $6.25B | $6.05B | · | $6.24B | |
| Liabilities + Equity | $16.94B | $16.67B | $16.23B | $16.20B | $15.97B | $15.80B | $16.15B | $16.09B | $13.88B | $13.95B | · | $13.48B | $13.43B | $12.79B | · | $13.22B | |
| Shares Outstanding | 110,000,000 | 111,000,000 | 110,000,000 | 111,000,000 | 112,000,000 | 112,000,000 | 111,000,000 | 112,000,000 | 111,000,000 | 111,000,000 | 111,000,000 | 112,000,000 | 112,000,000 | 112,000,000 | 111,000,000 | 114,000,000 |
キャッシュフロー
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $146M | $147M | $145M | $142M | $143M | $140M | $135M | $125M | $117M | $116M | $109M | $111M | $112M | $107M | $116M | $108M | |
| Stock-based Comp | $23M | $20M | $25M | $20M | $21M | $22M | $27M | $19M | $20M | $22M | $19M | $18M | $16M | $24M | $22M | $18M | |
| Deferred Tax | $-2M | $48M | $-13M | $110M | $1M | $7M | $34M | $15M | $-18M | $-18M | $-10M | $-23M | $-12M | $-4M | $-44M | $65M | |
| Amort. of Intangibles | $38M | $37M | $37M | $39M | $39M | $39M | $37M | $32M | $29M | $29M | $27M | $27M | $28M | $26M | $39M | $27M | |
| Restructuring | · | · | · | $6M | $1M | · | · | $7M | $8M | · | · | $1M | $1M | · | · | · | |
| Other Non-cash | · | $-189M | · | · | · | $-75M | · | · | · | $-160M | · | · | · | $-235M | · | · | |
| Operating Cash Flow | $597M | $278M | $465M | $563M | $544M | $314M | $464M | $356M | $360M | $154M | $527M | $207M | $444M | $94M | $334M | $502M | |
| CapEx | $138M | $114M | $158M | $144M | $108M | $117M | $123M | $106M | $92M | $104M | $72M | $105M | $104M | $127M | $147M | $118M | |
| Investing Cash Flow | $-134M | $-152M | $-191M | $-201M | $-124M | $-115M | $-502M | $-1.63B | $-200M | $-213M | $-114M | $-107M | $-682M | $-158M | $-174M | $-118M | |
| Stock Repurchased | · | · | $300M | $150M | · | · | $151M | · | · | · | $275M | $0 | $0 | $0 | $461M | $374M | |
| Net Stock Activity | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | · | · | |
| Dividends Paid | $96M | $88M | $90M | $89M | $90M | $84M | $84M | $84M | $84M | $79M | $80M | $80M | $80M | $74M | $75M | $78M | |
| Financing Cash Flow | $-229M | $-152M | $-287M | $-247M | $-293M | $-561M | $-170M | $1.77B | $-363M | $-153M | $130M | $-83M | $189M | $-76M | $-545M | $-474M | |
| Net Change in Cash | $233M | $-27M | $-12M | $113M | $131M | $-361M | $-215M | $493M | $-203M | $-212M | $543M | $17M | $-49M | $-140M | $-385M | $-90M | |
| Free Cash Flow | · | $164M | · | · | · | $197M | · | · | · | $50M | · | · | · | $-33M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $13M | · | · | · | $-61M | · | · |
収益性
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 15.1% | 13.8% | · | 13.7% | 15.9% | 13.1% | · | 13.3% | 14.8% | 12.7% | · | 14.9% | 14.9% | 13.1% | · | 15.8% | |
| Net Margin | 10.5% | 8.7% | · | 8.7% | 10.2% | 8.3% | · | 9.1% | 9.6% | 8.2% | · | 9.8% | 10.1% | 8.7% | · | 10.3% | |
| Pretax Margin | 13.5% | 11.5% | · | 11.7% | 13.9% | 10.4% | · | 11.9% | 13.1% | 11.2% | · | 13.0% | 13.6% | 11.9% | · | 14.1% | |
| EBITDA Margin | 19.9% | 18.9% | · | 18.8% | 21.0% | 18.3% | · | 18.3% | 19.7% | 17.6% | · | 19.7% | 19.7% | 17.7% | · | 20.1% | |
| ROA | 1.9% | 1.6% | · | 1.5% | 1.9% | 1.5% | · | 1.5% | 1.7% | 1.5% | · | 1.7% | 1.8% | 1.5% | · | 1.9% | |
| ROE | 4.3% | 3.5% | · | 3.5% | 4.1% | 3.3% | · | 3.4% | 3.6% | 3.1% | · | 3.5% | 3.7% | 3.2% | · | 4.0% | |
| ROIC | 2.7% | 4.0% | · | 3.8% | 4.2% | 3.9% | · | 2.0% | 3.8% | 3.1% | · | 3.9% | 3.9% | 3.9% | · | 4.8% |
流動性と支払能力
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.6 | 1.2 | · | 1.1 | 1.1 | 1.4 | · | 1.3 | 1.0 | 1.0 | · | 1.1 | 0.9 | 1.3 | · | 1.5 | |
| Quick Ratio | 1.3 | 0.9 | · | 0.9 | 0.9 | 1.1 | · | 1.0 | 0.8 | 0.8 | · | 0.9 | 0.7 | 1.1 | · | 1.2 | |
| Debt / Equity | 0.8 | 0.1 | · | 0.1 | 0.1 | 0.0 | · | 0.9 | 0.1 | 0.1 | · | 0.0 | 0.1 | 0.0 | · | 0.0 | |
| LT Debt / Equity | 0.7 | · | · | · | · | · | · | 0.8 | · | · | · | · | · | · | · | · | |
| Interest Coverage | · | · | · | · | · | · | · | · | 7.6 | 6.1 | · | 8.3 | 8.9 | 8.2 | · | 10.6 |
効率性
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | |
| Inventory Turnover | 9.6 | 9.4 | · | 10.1 | 9.9 | 9.7 | · | 9.1 | 8.7 | 8.6 | · | 8.4 | 8.3 | 8.1 | · | 8.3 | |
| Receivables Turnover | 2.0 | 1.9 | · | 2.0 | 2.0 | 1.9 | · | 1.9 | 1.9 | 1.8 | · | 1.8 | 1.8 | 1.8 | · | 1.8 |
1株あたり
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $68.33 | $66.36 | · | $65.39 | $64.54 | $61.87 | · | $60.79 | $59.61 | $57.95 | · | $57.37 | $55.79 | $54.02 | · | $54.69 | |
| Revenue / Share | $27.17 | $25.85 | · | $24.92 | $24.43 | $23.47 | · | $22.02 | $21.40 | $21.12 | · | $20.13 | $20.51 | $20.63 | · | $21.07 | |
| Cash Flow / Share | · | $2.48 | · | · | · | $2.78 | · | · | · | $1.38 | · | · | · | $0.83 | · | · | |
| Cash / Share | $5.69 | $3.54 | · | $3.89 | $2.85 | $1.68 | · | $6.82 | $2.44 | $4.27 | · | $1.28 | $1.12 | $1.56 | · | $6.14 | |
| Dividend / Share | $0.86 | $0.86 | $0.80 | $0.80 | $0.80 | $0.80 | $0.75 | $0.75 | $0.75 | $0.75 | $0.71 | $0.71 | $0.71 | $0.71 | $0.66 | $0.66 | |
| EPS (TTM) | $9.42 | $9.05 | · | $8.52 | $8.35 | $7.91 | · | $7.44 | $7.41 | $7.43 | · | $6.71 | $6.92 | $6.83 | · | $10.16 |
バリュエーション（TTM）
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $11.56B | $11.28B | · | $10.85B | $10.52B | $10.16B | · | $9.54B | $9.35B | $9.29B | · | $9.30B | $9.49B | $9.60B | · | $10.29B | |
| Net Income TTM | $1.06B | $1.02B | · | $969M | $950M | $897M | · | $841M | $840M | $846M | · | $763M | $794M | $793M | · | $1.24B | |
| Market Cap | $23.31B | $21.75B | · | $21.15B | $20.12B | $18.95B | · | $17.39B | $15.19B | $14.78B | · | $13.65B | $15.74B | $15.85B | · | $13.99B | |
| Enterprise Value | $28.33B | $21.86B | · | $21.23B | $20.30B | $18.76B | · | $22.88B | $15.53B | $15.21B | · | $13.81B | $16.13B | $15.67B | · | $13.29B | |
| P/E | 22.5 | 21.7 | · | 22.4 | 21.5 | 21.4 | · | 20.9 | 18.5 | 17.9 | · | 18.2 | 20.3 | 20.7 | · | 12.1 | |
| P/S | 2.0 | 1.9 | · | 1.9 | 1.9 | 1.9 | · | 1.8 | 1.6 | 1.6 | · | 1.5 | 1.7 | 1.7 | · | 1.4 | |
| P/B | 3.1 | 3.0 | · | 2.9 | 2.8 | 2.7 | · | 2.6 | 2.3 | 2.3 | · | 2.1 | 2.5 | 2.6 | · | 2.2 | |
| P / Cash Flow | · | 78.3 | · | · | · | 60.4 | · | · | · | 95.9 | · | · | · | 168.6 | · | · | |
| EV / Revenue | 2.5 | 1.9 | · | 2.0 | 1.9 | 1.8 | · | 2.4 | 1.7 | 1.6 | · | 1.5 | 1.7 | 1.6 | · | 1.3 | |
| Dividend Yield | 1.6% | 1.6% | · | 1.6% | 1.7% | 1.8% | · | 1.9% | 2.1% | 2.2% | · | 2.3% | 1.9% | 1.9% | · | 2.2% | |
| Earnings Yield | 4.4% | 4.6% | · | 4.5% | 4.7% | 4.7% | · | 4.8% | 5.4% | 5.6% | · | 5.5% | 4.9% | 4.8% | · | 8.3% | |
| Payout Ratio | · | 34.9% | · | · | · | 38.2% | · | · | · | 40.7% | · | · | · | 36.6% | · | · | |
| Annual Payout | $363M | $357M | · | $347M | $342M | $336M | · | $327M | $323M | $319M | · | $309M | $307M | $305M | · | $307M |
最新期間は左側 · null値は・として表示
財務諸表 損益計算書、貸借対照表、キャッシュフロー — 年次、過去5年間
| 指標 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 収益 | $11.04B | $9.87B | $9.25B | $9.88B | $10.79B |
| 営業利益率 % | 14.1% | 13.6% | 13.6% | 14.4% | 22.1% |
| 純利益 | $992M | $871M | $854M | $946M | $2.00B |
| 希薄化後EPS | $8.75 | $7.69 | $7.49 | $7.97 | $15.55 |
| 指標 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 負債資本倍率 | 0.8 | 0.9 | 0.7 | 0.7 | 0.6 |
| 流動比率 | 1.0 | 1.1 | 1.3 | 1.2 | 1.6 |
| クイックレシオ | 0.8 | 0.9 | 1.0 | 1.0 | 1.3 |
| 指標 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| フリーキャッシュフロー | $1.36B | $909M | $864M | $1.31B | $1.83B |
機関投資家（13F） 1,169 提出者 · $23.1B合計 · 時点 2026年9月30日
四半期SECフォーム13Fでこの株式の保有を報告している機関。ロングポジションのみ。単一の提出者は、別々のオプションレッグで2回表示される場合があります。 大きな反対売買のプット/コール・レッグは、通常、マーケットメイクまたはヘッジされた在庫を反映しており、方向性への確信を示すものではありません。
保有者
1,169
保有価値
$23.1B
新規ポジション
118
解消済みポジション
64
機関投資家の動向 — Q2 2026 対 前四半期
| 新規ポジション | 解消済みポジション | 増加 | 減少 | 純株式数増減 |
|---|---|---|---|---|
| 118 (-23 前期比) | 64 (-18 前期比) | 430 (+89 前期比) | 343 (-26 前期比) | +3.8M |
Q1 2026と比較しました。 SECフォーム13Fの提出期限は四半期末から45日後ですが、遅延提出者向けの短いバッファーが含まれます。この期間内の四半期は、直近で完全に報告されたペアを優先するためスキップされます。
| 機関投資家 | 評価額 | 株式数 | % 追跡された13Fのうち | タイプ |
|---|---|---|---|---|
| VANGUARD GROUP INC | $2,497,458,052 | 14,392,082 | 10.79% | 株式数 |
| BlackRock, Inc. | $1,965,923,399 | 9,275,411 | 8.49% | 株式数 |
| VANGUARD CAPITAL MANAGEMENT LLC | $1,533,117,858 | 7,233,394 | 6.62% | 株式数 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $1,299,474,988 | 6,131,045 | 5.61% | 株式数 |
| STATE STREET CORP | $1,169,252,484 | 5,516,643 | 5.05% | 株式数 |
| Boston Partners | $1,004,552,880 | 4,744,473 | 4.34% | 株式数 |
| JPMORGAN CHASE & CO | $748,586,197 | 3,520,438 | 3.23% | 株式数 |
| GEODE CAPITAL MANAGEMENT, LLC | $662,582,607 | 3,137,873 | 2.86% | 株式数 |
| MORGAN STANLEY | $521,503,271 | 2,460,497 | 2.25% | 株式数 |
| EdgePoint Investment Group Inc. | $476,372,038 | 2,247,568 | 2.06% | 株式数 |
| DIMENSIONAL FUND ADVISORS LP | $421,376,156 | 1,988,048 | 1.82% | 株式数 |
| BANK OF AMERICA CORP /DE/ | $410,151,497 | 1,935,133 | 1.77% | 株式数 |
| Grantham, Mayo, Van Otterloo & Co. LLC | $400,206,122 | 1,888,207 | 1.73% | 株式数 |
| WELLS FARGO & COMPANY/MN | $371,171,119 | 1,751,220 | 1.60% | 株式数 |
| Davis Selected Advisers | $329,781,509 | 1,555,612 | 1.42% | 株式数 |
| VICTORY CAPITAL MANAGEMENT INC | $311,037,928 | 1,467,506 | 1.34% | 株式数 |
| NORGES BANK | $298,133,109 | 1,406,620 | 1.29% | 株式数 |
| FMR LLC | $296,462,102 | 1,398,735 | 1.28% | 株式数 |
| Invesco Ltd. | $292,303,423 | 1,379,115 | 1.26% | 株式数 |
| NORTHERN TRUST CORP | $238,963,873 | 1,127,454 | 1.03% | 株式数 |
| GOLDMAN SACHS GROUP INC | $208,282,052 | 982,694 | 0.90% | 株式数 |
| UBS Group AG | $188,403,627 | 888,906 | 0.81% | 株式数 |
| AMERICAN CENTURY COMPANIES INC | $173,422,135 | 818,220 | 0.75% | 株式数 |
| M&G PLC | $168,677,800 | 795,650 | 0.73% | 株式数 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $165,917,256 | 846,603 | 0.72% | 株式数 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $163,988,047 | 773,711 | 0.71% | 株式数 |
| AMERIPRISE FINANCIAL INC | $161,076,730 | 759,975 | 0.70% | 株式数 |
| Legal & General Group Plc | $151,986,161 | 717,085 | 0.66% | 株式数 |
| Bank of New York Mellon Corp | $133,388,337 | 629,339 | 0.58% | 株式数 |
| VANGUARD FIDUCIARY TRUST CO | $131,756,386 | 621,639 | 0.57% | 株式数 |
| DEUTSCHE BANK AG\ | $124,180,445 | 585,895 | 0.54% | 株式数 |
| ALLIANCEBERNSTEIN L.P. | $122,662,706 | 625,894 | 0.53% | 株式数 |
| Nuveen, LLC | $119,503,667 | 563,830 | 0.52% | 株式数 |
| PRINCIPAL FINANCIAL GROUP INC | $109,630,811 | 517,225 | 0.47% | 株式数 |
| RAYMOND JAMES FINANCIAL INC | $107,196,222 | 505,762 | 0.46% | 株式数 |
| Amundi | $105,710,274 | 498,751 | 0.46% | 株式数 |
| Woodline Partners LP | $102,974,000 | 485,841 | 0.44% | 株式数 |
| FIDUCIARY MANAGEMENT INC /WI/ | $102,489,906 | 483,557 | 0.44% | 株式数 |
| Artemis Investment Management LLP | $99,175,856 | 467,921 | 0.43% | 株式数 |
| CRAWFORD INVESTMENT COUNSEL INC | $97,514,204 | 460,081 | 0.42% | 株式数 |
| BARCLAYS PLC | $95,107,474 | 448,726 | 0.41% | 株式数 |
| ENVESTNET ASSET MANAGEMENT INC | $90,834,224 | 428,564 | 0.39% | 株式数 |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $88,822,918 | 417,715 | 0.38% | 株式数 |
| BNP PARIBAS FINANCIAL MARKETS | $83,772,178 | 395,245 | 0.36% | 株式数 |
| M.D. Sass, LLC | $76,397,960 | 360,453 | 0.33% | 株式数 |
| Qube Research & Technologies Ltd | $72,783,206 | 343,398 | 0.31% | 株式数 |
| MACKENZIE FINANCIAL CORP | $70,641,875 | 333,295 | 0.31% | 株式数 |
| Advisors Capital Management, LLC | $69,429,626 | 327,575 | 0.30% | 株式数 |
| CITIGROUP INC | $66,888,058 | 315,584 | 0.29% | 株式数 |
| Swiss National Bank | $65,683,305 | 309,900 | 0.28% | 株式数 |
アクティビストおよび5%超のオーナー 13保有
SECスケジュール13Dを提出した投資家 — 発行体の影響を与える意図（アクティビストの保有、取締役会キャンペーン、M&A）を持つ5%超の受益権所有。各行は、その提出者のポジションの最新の既知の状態を示します。
| 提出者 | 提出済み | 保有 | ステータス | 目的 | 提出書類 |
|---|---|---|---|---|---|
| Quest Diagnostics Incorporated | 2011年5月18日 | · | 初回提出 | M&A / 売却 | SEC |
| 未開示の報告者 | 2011年2月1日 | · | 初回提出 | 受動的投資 | SEC |
| 未開示の報告者 | 2009年3月20日 | · | 初回提出 | · | SEC |
| GlaxoSmithKline plc ×2 提出書類 | 2008年9月18日 | · | 初回提出 | · | SEC |
| 未開示の報告者 | 2007年2月16日 | · | 初回提出 | · | SEC |
| Quest Diagnostics Incorporated - (FEIN No. ×2 提出書類 | 2006年1月19日 | · | 初回提出 | · | SEC |
| 未開示の報告者 | 2004年12月15日 | · | 初回提出 | · | SEC |
| 未開示の報告者 | 2004年6月29日 | · | 初回提出 | · | SEC |
| 未開示の報告者 | 2002年6月24日 | · | 初回提出 | M&A / 売却 | SEC |
| 未開示の報告者 | 2002年5月22日 | · | 初回提出 | · | SEC |
| 未開示の報告者 | 2002年4月12日 | · | 初回提出 | M&A / 売却 | SEC |
| IRS Identification Nos. of Above Persons (entities only) Quest Diagnostics Ventures LLC - (FEIN No., Quest Diagnostics Incorporated - (FEIN No. ×3 提出書類 | 2001年11月1日 | · | 初回提出 | M&A / 売却 | SEC |
| 未開示の報告者 | 2001年5月14日 | · | 初回提出 | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
企業インサイダー 52 人のインサイダー · 26人の役員 · 26人の取締役
| インサイダー | 役職 | 最終アクティビティ | 保有株式数 | 12ヶ月購入 | 12ヶ月売却 | 12ヶ月純額 |
|---|---|---|---|---|---|---|
| E. J. Davis | CEO and President | 2026年9月1日 S | 122,423 | 0 | 6 | $-17,083,502 |
| Surya N Mohapatra | Chairman, President & CEO | 2012年4月30日 F | 243,713 | 0 | 0 | $0 |
| Sam Samad | Executive Vice President & CFO | 2026年7月22日 A | 33,478 | 0 | 0 | $0 |
| Mark Guinan | Executive Vice President & CFO | 2022年3月7日 F | 98,981 | 0 | 0 | $0 |
| Robert Hagemann | SVP & Chief Financial Officer | 2013年3月5日 F | 126,722 | 0 | 0 | $0 |
| Michael E Prevoznik | SVP & General Counsel | 2026年8月28日 M | 36,557 | 0 | 6 | $-6,649,682 |
| Mark E Delaney | SVP & Chief Commercial Officer | 2026年7月28日 S | 10,335 | 0 | 2 | $-1,864,971 |
| Karthik Kuppusamy | SVP, Clinical Solutions | 2026年7月22日 L | 13,557 | 0 | 2 | $-2,167,772 |
| Patrick Plewman | SVP for Diagnostic Services | 2026年7月22日 L | 15,293 | 0 | 4 | $-2,025,174 |
| Catherine T. Doherty | EVP, Regional Businesses | 2026年3月5日 S | 67,122 | 0 | 8 | $-6,964,749 |
| Michael J Deppe | SVP, Corp. Controller & CAO | 2026年3月4日 F | 35,196 | 0 | 0 | $0 |
| Mark A Gardner | SVP of Molecular Gen & Oncol | 2024年9月24日 F | 4,673 | 0 | 0 | $0 |
| Manner Carrie Eglinton | SVP, Advanced Diagnostics | 2022年3月7日 F | 48,391 | 0 | 0 | $0 |
| Manuel O. Mendez | SVP & Chief Commercial Officer | 2021年2月17日 A | 29,045 | 0 | 0 | $0 |
| Robert A Klug | VP, Corporate Controller | 2019年3月1日 F | 6,261 | 0 | 0 | $0 |
| Jon R Cohen | SVP & Group Exec. Diag. Sol. | 2018年3月8日 M | 31,757 | 0 | 0 | $0 |
| Everett Cunningham | SVP, Commercial | 2018年3月1日 G | 37,760 | 0 | 0 | $0 |
| Thomas F Bongiorno | VP and Corporate Controller | 2015年3月2日 F | 11,837 | 0 | 0 | $0 |
| John B. Haydon | SVP, Operations | 2014年2月13日 A | 19,890 | 0 | 0 | $0 |
| Kathy Ordonez | SVP, Diagnostic Solutions | 2013年3月31日 F | 9,569 | 0 | 0 | $0 |
| Joan Elizabeth Miller | SVP-Oncology & Neurology Srvcs | 2012年2月29日 F | 89,232 | 0 | 0 | $0 |
| Wayne R. Simmons | Vice President, Operations | 2011年6月16日 M | 47,150 | 0 | 0 | $0 |
| Robert E Peters | VP, Sales & Marketing | 2007年2月12日 A | 12,974 | 0 | 0 | $0 |
| David M Zewe | SVP, Diagnostic Testing Ops | 2007年2月12日 A | 31,079 | 0 | 0 | $0 |
| GRANT THOMAS W II | Sr VP, Ins. & Employer Serv. | 2007年2月12日 A | · | 0 | 0 | $0 |
| Gerald C Marrone | SVP, Administration | 2004年2月28日 F | 49,609 | 0 | 0 | $0 |
| Timothy C Wentworth | 取締役 | 2026年10月1日 A | 1,358 | 0 | 0 | $0 |
| Wright Lassiter III | 取締役 | 2026年7月22日 L | 10,323 | 0 | 0 | $0 |
| Vicky B Gregg | 取締役 | 2026年7月22日 A | 18,386 | 0 | 1 | $-239,700 |
| Robert B Carter | 取締役 | 2026年7月22日 L | 3,864 | 0 | 0 | $0 |
| Timothy L Main | 取締役 | 2026年7月22日 L | 22,460 | 0 | 0 | $0 |
| Luis Diaz | 取締役 | 2026年5月20日 A | 5,196 | 0 | 0 | $0 |
| Tracey Doi | 取締役 | 2026年5月20日 A | 7,748 | 0 | 0 | $0 |
| Timothy M Ring | 取締役 | 2026年5月20日 A | 31,140 | 0 | 0 | $0 |
| Gary M Pfeiffer | 取締役 | 2026年5月20日 A | 31,005 | 0 | 1 | $-270,317 |
| Gail R Wilensky | 取締役 | 2023年5月17日 A | 20,506 | 0 | 0 | $0 |
| Stephen H Rusckowski | 取締役 | 2023年3月6日 F | 389,597 | 0 | 0 | $0 |
| Helen Torley | 取締役 | 2021年5月25日 A | 6,260 | 0 | 0 | $0 |
| Daniel Stanzione | 取締役 | 2020年11月23日 S | 28,349 | 0 | 0 | $0 |
| Jenne K Britell | 取締役 | 2018年6月4日 G | 14,479 | 0 | 0 | $0 |
| Jeffrey M Leiden | 取締役 | 2018年5月29日 S | 6,000 | 0 | 0 | $0 |
| John B Ziegler | 取締役 | 2017年2月22日 S | 16,557 | 0 | 0 | $0 |
| John C Baldwin MD | 取締役 | 2015年8月12日 S | 12,949 | 0 | 0 | $0 |
| William F Buehler | 取締役 | 2014年2月12日 M | 26,225 | 0 | 0 | $0 |
| GSK plc | 取締役 | 2011年1月31日 S | 0 | 0 | 0 | $0 |
| Rosanne Haggerty | 取締役 | 2010年5月6日 A | 9,334 | 0 | 0 | $0 |
| William R Grant | 取締役 | 2007年4月1日 A | 3,334 | 0 | 0 | $0 |
| James F Flaherty III | 取締役 | 2006年5月4日 A | 1,667 | 0 | 0 | $0 |
| Kenneth D Brody | 取締役 | 2004年4月28日 S | 0 | 0 | 0 | $0 |
| Mary A Cirillo | 取締役 | 2004年4月1日 A | 2,627 | 0 | 0 | $0 |
| Denise M Morrison | · | 2026年5月20日 A | 11,929 | 0 | 0 | $0 |
| FREEMAN KENNETH W/NJ | · | 2004年12月14日 F | 216,187 | 0 | 0 | $0 |
SECフォーム3/4/5提出書類からのインサイダー；純額＝公開市場のP/Sのみ
ETF保有状況 133のETFが保有
ウェイトは直接株式保有（N-PORT）のみを反映しています。レバレッジ型またはデリバティブベースのファンドは、表示されていない追加のスワップエクスポージャーを保有している可能性があります。
| ファンド | ウェイト | 単位 | 時点 | ソース |
|---|---|---|---|---|
| IHF · iShares Trust | 3.75% | 212,725 SH | 2026年9月11日 | 日次 |
| RW · EA Series Trust | 2.50% | 1,865 NS | 2026年7月31日 | N-PORT |
| RSPH · Invesco Exchange-Traded Fund Trust | 1.62% | 60,612 SH | 2026年10月1日 | 日次 |
| FXH · First Trust Exchange-Traded AlphaDE… | 1.49% | 67,178 NS | 2026年7月31日 | N-PORT |
| CZA · Invesco Exchange-Traded Fund Trust | 1.28% | 9,293 SH | 2026年10月1日 | 日次 |
| NUDV · Nushares ETF Trust | 1.09% | 2,338 NS | 2026年7月31日 | N-PORT |
| LSEQ · Harbor ETF Trust | 0.97% | 637 NS | 2026年7月31日 | N-PORT |
| SPLV · Invesco Exchange-Traded Fund Trust … | 0.89% | 263,892 SH | 2026年10月1日 | 日次 |
| SPVM · Invesco Exchange-Traded Fund Trust | 0.80% | 4,469 SH | 2026年10月1日 | 日次 |
| JOET · Virtus ETF Trust II | 0.78% | 8,139 NS | 2026年7月31日 | N-PORT |
| ESMV · iShares Trust | 0.70% | 236 SH | 2026年9月11日 | 日次 |
| QLV · FlexShares Trust | 0.63% | 4,452 NS | 2026年7月31日 | N-PORT |
| HUSV · First Trust Exchange-Traded Fund III | 0.60% | 1,903 NS | 2026年7月31日 | N-PORT |
| COWZ · Pacer Funds Trust | 0.46% | 369,448 NS | 2026年7月31日 | N-PORT |
| JPME · J.P. Morgan Exchange-Traded Fund Tr… | 0.43% | 8,600 NS | 2026年7月31日 | N-PORT |
| JPUS · J.P. Morgan Exchange-Traded Fund Tr… | 0.43% | 8,453 NS | 2026年7月31日 | N-PORT |
| IYH · iShares Trust | 0.41% | 64,629 SH | 2026年9月11日 | 日次 |
| VOE · VANGUARD INDEX FUNDS | 0.40% | 711,079 SH | 2026年8月19日 | 日次 |
| FTA · First Trust Exchange-Traded AlphaDE… | 0.38% | 22,688 NS | 2026年7月31日 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0.37% | 52,313 NS | 2026年7月31日 | N-PORT |
| IMCV · iShares Trust | 0.36% | 18,030 SH | 2026年9月11日 | 日次 |
| SUSA · iShares Trust | 0.34% | 59,240 SH | 2026年9月11日 | 日次 |
| VHT · VANGUARD WORLD FUND | 0.34% | 330,273 SH | 2026年8月19日 | 日次 |
| IXJ · iShares Trust | 0.32% | 58,047 SH | 2026年9月11日 | 日次 |
| DFLV · Dimensional ETF Trust | 0.30% | 87,905 NS | 2026年7月31日 | N-PORT |
| FEX · First Trust Exchange-Traded AlphaDE… | 0.30% | 19,944 NS | 2026年7月31日 | N-PORT |
| CURE · Direxion Shares ETF Trust | 0.30% | 2,178 NS | 2026年7月31日 | N-PORT |
| EQIN · Columbia ETF Trust I | 0.27% | 3,540 NS | 2026年7月31日 | N-PORT |
| JVAL · J.P. Morgan Exchange-Traded Fund Tr… | 0.26% | 9,337 NS | 2026年7月31日 | N-PORT |
| JMOM · J.P. Morgan Exchange-Traded Fund Tr… | 0.26% | 27,542 NS | 2026年7月31日 | N-PORT |
| BSCT · Invesco Exchange-Traded Self-Indexe… | 0.25% | 7,574,000 | 2026年10月1日 | 日次 |
| IWS · iShares Trust | 0.25% | 165,299 SH | 2026年9月11日 | 日次 |
| ESUM · Strategy Shares | 0.24% | 1,901 NS | 2026年7月31日 | N-PORT |
| SIZE · iShares Trust | 0.24% | 4,359 SH | 2026年9月11日 | 日次 |
| VO · VANGUARD INDEX FUNDS | 0.23% | 2,398,948 SH | 2026年8月19日 | 日次 |
| VFMV · VANGUARD WELLINGTON FUND | 0.22% | 4,307 SH | 2026年8月19日 | 日次 |
| RSP · Invesco Exchange-Traded Fund Trust | 0.20% | 831,602 SH | 2026年10月1日 | 日次 |
| ACWV · iShares, Inc. | 0.20% | 28,973 SH | 2026年9月11日 | 日次 |
| EUSA · iShares, Inc. | 0.19% | 16,140 SH | 2026年9月11日 | 日次 |
| FAB · First Trust Exchange-Traded AlphaDE… | 0.19% | 1,371 NS | 2026年7月31日 | N-PORT |
| IWR · iShares Trust | 0.19% | 452,857 SH | 2026年9月11日 | 日次 |
| IMCB · iShares Trust | 0.18% | 12,959 SH | 2026年9月11日 | 日次 |
| MTUM · iShares Trust | 0.16% | 168,369 SH | 2026年9月11日 | 日次 |
| DFVX · Dimensional ETF Trust | 0.16% | 3,609 NS | 2026年7月31日 | N-PORT |
| DFUV · Dimensional ETF Trust | 0.15% | 97,399 NS | 2026年7月31日 | N-PORT |
| ESLG · Strategy Shares | 0.15% | 146 NS | 2026年7月31日 | N-PORT |
| XOEF · iShares Trust | 0.15% | 140 SH | 2026年9月11日 | 日次 |
| CATH · Global X Funds | 0.12% | 6,867 NS | 2026年7月31日 | N-PORT |
| PFIG · Invesco Exchange-Traded Fund Trust … | 0.12% | 165,000 | 2026年10月1日 | 日次 |
| ROUS · Lattice Strategies Trust | 0.12% | 3,633 NS | 2026年7月31日 | N-PORT |
| SPMO · Invesco Exchange-Traded Fund Trust … | 0.12% | 114,981 SH | 2026年10月1日 | 日次 |
| EVUS · iShares Trust | 0.11% | 1,865 SH | 2026年9月11日 | 日次 |
| VIG · VANGUARD SPECIALIZED FUNDS | 0.10% | 625,384 SH | 2026年8月19日 | 日次 |
| VYM · VANGUARD WHITEHALL FUNDS | 0.10% | 440,583 SH | 2026年8月19日 | 日次 |
| DGRO · iShares Trust | 0.10% | 179,879 SH | 2026年9月11日 | 日次 |
| EQAL · Invesco Exchange-Traded Fund Trust … | 0.10% | 3,265 SH | 2026年10月1日 | 日次 |
| PFM · Invesco Exchange-Traded Fund Trust | 0.10% | 3,153 SH | 2026年10月1日 | 日次 |
| VTV · VANGUARD INDEX FUNDS | 0.09% | 1,051,572 SH | 2026年8月19日 | 日次 |
| DXUV · Dimensional ETF Trust | 0.09% | 2,092 NS | 2026年7月31日 | N-PORT |
| CRBN · iShares Trust | 0.09% | 4,406 SH | 2026年9月11日 | 日次 |
| DCOR · Dimensional ETF Trust | 0.09% | 12,279 NS | 2026年7月31日 | N-PORT |
| IVE · iShares Trust | 0.09% | 183,297 SH | 2026年9月11日 | 日次 |
| IUSV · iShares Trust | 0.08% | 97,344 SH | 2026年9月11日 | 日次 |
| DFAC · Dimensional ETF Trust | 0.08% | 167,227 NS | 2026年7月31日 | N-PORT |
| VOOV · VANGUARD ADMIRAL FUNDS | 0.08% | 25,423 SH | 2026年8月19日 | 日次 |
| CHRI · Global X Funds | 0.08% | 27 NS | 2026年7月31日 | N-PORT |
| IQSU · New York Life Investments ETF Trust | 0.08% | 1,095 NS | 2026年7月31日 | N-PORT |
| IUS · Invesco Exchange-Traded Self-Indexe… | 0.08% | 3,149 SH | 2026年10月1日 | 日次 |
| SUSL · iShares Trust | 0.08% | 3,907 SH | 2026年9月11日 | 日次 |
| ILCV · iShares Trust | 0.07% | 4,337 SH | 2026年9月11日 | 日次 |
| DSI · iShares Trust | 0.07% | 16,854 SH | 2026年9月11日 | 日次 |
| VONV · VANGUARD SCOTTSDALE FUNDS | 0.07% | 66,643 SH | 2026年8月19日 | 日次 |
| IWD · iShares Trust | 0.07% | 245,078 SH | 2026年9月11日 | 日次 |
| HDUS · Lattice Strategies Trust | 0.07% | 586 NS | 2026年7月31日 | N-PORT |
| EGLE · Global X Funds | 0.06% | 6 NS | 2026年7月31日 | N-PORT |
| GLBL · Pacer Funds Trust | 0.06% | 3 NS | 2026年7月31日 | N-PORT |
| PRF · Invesco Exchange-Traded Fund Trust | 0.06% | 24,838 SH | 2026年10月1日 | 日次 |
| RWL · Invesco Exchange-Traded Fund Trust … | 0.06% | 24,515 SH | 2026年10月1日 | 日次 |
| DFSU · Dimensional ETF Trust | 0.05% | 5,056 NS | 2026年7月31日 | N-PORT |
| DFAU · Dimensional ETF Trust | 0.05% | 26,447 NS | 2026年7月31日 | N-PORT |
| OMFL · Invesco Exchange-Traded Self-Indexe… | 0.05% | 9,881 SH | 2026年10月1日 | 日次 |
| TOPC · iShares Trust | 0.05% | 68 SH | 2026年9月11日 | 日次 |
| XVV · iShares Trust | 0.04% | 1,285 SH | 2026年9月11日 | 日次 |
| XYLD · Global X Funds | 0.04% | 6,096 NS | 2026年7月31日 | N-PORT |
| QVML · Invesco Exchange-Traded Fund Trust … | 0.04% | 3,107 SH | 2026年10月1日 | 日次 |
| BKLC · BNY Mellon ETF Trust | 0.04% | 9,574 NS | 2026年7月31日 | N-PORT |
| BBUS · J.P. Morgan Exchange-Traded Fund Tr… | 0.04% | 15,319 NS | 2026年7月31日 | N-PORT |
| VOO · VANGUARD INDEX FUNDS | 0.04% | 2,875,103 SH | 2026年8月19日 | 日次 |
| VV · VANGUARD INDEX FUNDS | 0.04% | 129,285 SH | 2026年8月19日 | 日次 |
| ESGV · VANGUARD WORLD FUND | 0.04% | 24,972 SH | 2026年8月19日 | 日次 |
| TOV · EA Series Trust | 0.04% | 426 NS | 2026年7月31日 | N-PORT |
| PTLC · Pacer Funds Trust | 0.04% | 5,593 NS | 2026年7月31日 | N-PORT |
| VOTE · TCW ETF Trust | 0.04% | 1,876 NS | 2026年7月31日 | N-PORT |
| XYLG · Global X Funds | 0.04% | 109 NS | 2026年7月31日 | N-PORT |
| PBP · Invesco Exchange-Traded Fund Trust | 0.04% | 655 SH | 2026年10月1日 | 日次 |
| PBUS · Invesco Exchange-Traded Fund Trust … | 0.04% | 19,144 SH | 2026年10月1日 | 日次 |
| XCLR · Global X Funds | 0.04% | 6 NS | 2026年7月31日 | N-PORT |
| IVV · iShares Trust | 0.04% | 1,392,389 SH | 2026年9月11日 | 日次 |
| XTR · Global X Funds | 0.04% | 8 NS | 2026年7月31日 | N-PORT |
| ILCB · iShares Trust | 0.04% | 2,144 SH | 2026年9月11日 | 日次 |
| XRMI · Global X Funds | 0.04% | 82 NS | 2026年7月31日 | N-PORT |
| DFUS · Dimensional ETF Trust | 0.04% | 33,588 NS | 2026年7月31日 | N-PORT |
| SPUU · Direxion Shares ETF Trust | 0.04% | 417 NS | 2026年7月31日 | N-PORT |
| QDPL · Pacer Funds Trust | 0.04% | 2,663 NS | 2026年7月31日 | N-PORT |
| IWB · iShares Trust | 0.04% | 76,198 SH | 2026年9月11日 | 日次 |
| VOXP · Advisors Series Trust | 0.04% | 9 NS | 2026年7月31日 | N-PORT |
| IYY · iShares Trust | 0.04% | 4,688 SH | 2026年9月11日 | 日次 |
| IWV · iShares Trust | 0.03% | 30,298 SH | 2026年9月11日 | 日次 |
| ITOT · iShares Trust | 0.03% | 141,099 SH | 2026年9月11日 | 日次 |
| PHDG · Invesco Actively Managed Exchange-T… | 0.03% | 88 SH | 2026年10月1日 | 日次 |
| HCMT · Direxion Shares ETF Trust | 0.03% | 772 NS | 2026年7月31日 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0.03% | 3,515,122 SH | 2026年8月19日 | 日次 |
| VONE · VANGUARD SCOTTSDALE FUNDS | 0.03% | 18,213 SH | 2026年8月19日 | 日次 |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.03% | 9,300 SH | 2026年8月19日 | 日次 |
| SPXL · Direxion Shares ETF Trust | 0.03% | 8,650 NS | 2026年7月31日 | N-PORT |
| URTH · iShares, Inc. | 0.03% | 10,177 SH | 2026年9月11日 | 日次 |
| TILT · FlexShares Trust | 0.03% | 2,686 NS | 2026年7月31日 | N-PORT |
| TOK · iShares Trust | 0.03% | 292 SH | 2026年9月11日 | 日次 |
| ACWI · iShares Trust | 0.03% | 36,161 SH | 2026年9月11日 | 日次 |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0.02% | 95,097 SH | 2026年8月19日 | 日次 |
| DYNF · BlackRock ETF Trust | 0.02% | 34,844 SH | 2026年9月11日 | 日次 |
| GTO · Invesco Actively Managed Exchange-T… | 0.00% | 1,000 | 2026年9月30日 | 日次 |
| BIV · VANGUARD BOND INDEX FUNDS | · | · | 2026年7月15日 | 日次 |
| BSV · VANGUARD BOND INDEX FUNDS | · | · | 2026年7月15日 | 日次 |
| BND · VANGUARD BOND INDEX FUNDS | · | · | 2026年7月15日 | 日次 |
| VCRB · VANGUARD MALVERN FUNDS | · | · | 2026年7月15日 | 日次 |
| VSDB · VANGUARD MALVERN FUNDS | · | · | 2026年7月15日 | 日次 |
| VCSH · VANGUARD SCOTTSDALE FUNDS | · | · | 2026年7月15日 | 日次 |
| VCIT · VANGUARD SCOTTSDALE FUNDS | · | · | 2026年7月15日 | 日次 |
| VCLT · VANGUARD SCOTTSDALE FUNDS | · | · | 2026年7月15日 | 日次 |
| VTC · VANGUARD SCOTTSDALE FUNDS | · | · | 2026年7月30日 | 日次 |
| BNDW · VANGUARD SCOTTSDALE FUNDS | · | · | 2026年7月30日 | 日次 |
| VCEB · VANGUARD WORLD FUND | · | · | 2026年7月30日 | 日次 |
DGX アナリストコンセンサス 強気・弱気のアナリストの見解、12ヶ月の目標株価、アップサイド
レーティング · 23 アナリスト
買い
中央値ターゲット
$250.00
+7.1%
6 26.1%
強い買い
7 30.4%
買い
10 43.5%
保有
0 0.0%
売り
0 0.0%
強い売り
12ヶ月目標株価
15 アナリスト · 2026-09-27平均値ターゲット $247.73 +6.2%
現在
現在価格 $233.33
安値$204.00
平均値$247.73
高値$265.00
同業他社比較（GICSサブインダストリー） 主要メトリクスとセクターピアの比較
FY基準、価格は各社の直近年度末終値。
| ティッカー | 時価総額 | P/E | 売上高 YoY | 純利益率 | ROE | 粗利益率 |
|---|---|---|---|---|---|---|
| DGX | $19.09B | 19.8 | 11.8% | 9.0% | 14.2% | · |
| CVS | $100.87B | 57.1 | 7.8% | 0.44% | 2.4% | · |
| CI | $72.51B | 12.4 | 11.2% | 2.2% | 14.4% | · |
| LH | $20.62B | 24.0 | 7.2% | 6.3% | 10.3% | 28.8% |
| GH | $13.34B | -30.8 | 32.9% | -42.4% | 205.7% | · |
| LH | $20.62B | 24.0 | 7.2% | 6.3% | 10.3% | 28.8% |
| BTSG | $7.20B | 43.0 | 28.2% | 1.5% | 10.8% | 11.8% |
| DVA | $7.79B | 11.5 | 6.5% | 5.5% | -281.8% | · |
| HNGE | $0 | -6.0 | 50.6% | -89.9% | -299.8% | 79.7% |
| HIMS | · | 63.7 | 59.0% | 5.5% | 23.3% | 73.8% |
| CHE | · | 23.3 | 4.1% | 10.5% | 24.4% | · |
最新ニュース この会社に言及した最近の見出し
マイ指標 あなた専用のウォッチリスト — 決算詳細から選択した行
重視する指標を選択してください — 上記の「財務諸表」の任意の行の横にある「+」をクリックしてください。
選択内容は保存され、すべてのティッカーで引き継がれます。
出典：SEC 10-Q 提出日 7月 23, 2026